Wang Ximing, Song Na, Zhang Ye, Cai Ying, Liu Yunpeng, Qu Xiujuan, Li Zhi, Li Danni, Hou Kezuo, Kang Jian, Hu Xuejun
Department of Respiratory and Infectious disease of Geriatrics, The First Hospital of China Medical University, Shenyang, 110001, China.
Department of Medical Oncology, The First Hospital of China Medical University, No.155, North Nanjing Street, Heping District, Shenyang, 110001, China.
Tumour Biol. 2015 Sep;36(9):7053-9. doi: 10.1007/s13277-015-3404-4. Epub 2015 Apr 14.
Despite considerable advances in chemotherapy, radiotherapy, target therapy, and biological therapy, the prognosis for those with resected non-small-cell lung cancer (NSCLC) has not substantially improved. It was recently reported that two receptors, Notch-1 and c-Met, correlate directly or indirectly with the initiation and development of malignant tumors, such as lung cancer; however, the prognostic value of coexpression of these receptors and their relationship in resected NSCLC was not clear. In this study, the expression levels of Notch-1 and c-Met in 117 patients with resected NSCLC were assessed using immunohistochemistry (IHC). The results showed that the positive expression rate of Notch-1 in total patients was 59.8 %. The positive expression rate of c-Met in the all population was 69.2 %. In addition, a significant positive association was shown between Notch-1 and c-Met (P < 0.001). Simultaneously, patients with coexpression of both receptors had a significantly poorer prognosis than those without coexpression (P < 0.001). Multivariate analysis showed that T stage (P = 0.016) and c-Met expression (P < 0.001) were independent prognostic factors. In conclusion, coexpression of both receptors correlates with poorer prognosis in patients with resected NSCLC. Targeting both receptors simultaneously may prove a more effective antitumor strategy. Patients with coexpression of both receptors might benefit from cotargeting Notch-1 and c-Met.
尽管在化疗、放疗、靶向治疗和生物治疗方面取得了显著进展，但接受手术切除的非小细胞肺癌（NSCLC）患者的预后并未得到实质性改善。最近有报道称，Notch-1和c-Met这两种受体与肺癌等恶性肿瘤的发生和发展直接或间接相关；然而，这些受体在接受手术切除的NSCLC中的共表达的预后价值及其关系尚不清楚。在本研究中，采用免疫组织化学（IHC）方法评估了117例接受手术切除的NSCLC患者中Notch-1和c-Met的表达水平。结果显示，所有患者中Notch-1的阳性表达率为59.8%。所有人群中c-Met的阳性表达率为69.2%。此外，Notch-1和c-Met之间存在显著的正相关（P < 0.001）。同时，两种受体共表达的患者预后明显比未共表达的患者差（P < 0.001）。多因素分析显示，T分期（P = 0.016）和c-Met表达（P < 0.001）是独立的预后因素。总之，两种受体的共表达与接受手术切除的NSCLC患者的较差预后相关。同时靶向这两种受体可能是一种更有效的抗肿瘤策略。两种受体共表达的患者可能从同时靶向Notch-1和c-Met中获益。
